BENGALURU – The trial demonstrated exceptional potential for TBA-7371 in combating TB, indicating robust bactericidal activity with just 14 days of treatment among patients with drug-susceptible pulmonary tuberculosis. Notably, the compound was well-tolerated, displaying significant dose-dependent efficacy, marking a pivotal leap forward in TB therapeutics.
FNDR, a prominent not-for-profit biotech R&D organization, spearheads the quest for pioneering therapeutics, diagnostics, and devices targeting diseases with profound socio-economic impacts. Since its establishment in 2014, FNDR has curated a diverse therapeutic portfolio spanning diseases like TB, malaria, dengue, COVID-19, and others, encompassing early-stage discovery to advanced clinical trials.
Read More
- Childhood high blood pressure doubles in 20 years as obesity crisis deepens, 114 million children affected
- Medical team performs Oman’s first artificial heart transplant at Royal Hospital
- 38-year-old Nigerian patient with rare skull base tumour successfully treated at Aster Royal Al Raffah Hospital in complex 11-hour surgery
- Royal Hospital marks milestone with Oman’s first robotic surgery
- Walk your way to better health and happiness
